Granted Patent B2

US 12,459,992 · App. 17/150,005 · Granted Nov 4, 2025

Inventors: Camille Bedrosian (Woodbridge, CT); Fanny O'Brien (Norwell, MA); Jing Jing Wang (Woodbridge, CT)

Assignee: Alexion Pharmaceuticals, Inc.

C07K16/18A61M1/3496A61K2039/505A61K2039/54A61K2039/545A61K2039/55C07K2317/24

Abstract

Claims (23)

1 . A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering a therapeutically effective amount of an eculizumab variant comprising a heavy chain amino acid sequence according to SEQ ID NO: 14 and a light chain amino acid sequence according to SEQ ID NO: 11 to the patient;

wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR); and

wherein the patient is administered the eculizumab variant for at least 26 weeks.

2 . The method of claim 1 , wherein the eculizumab variant is administered at a dose between 600 mg and 6000 mg; and

wherein the patient is administered the eculizumab variant for at least 26 weeks.

3 . The method of claim 1 , wherein the patient experiences a clinically meaningful improvement (reduction) in Myasthenia Gravis Activities of Daily Living (MG-ADL) score, in quantitative Myasthenia Gravis score (QMG), in Myasthenia Gravis Composite (MGC) score, in quality of life as measured by Myasthenia Gravis Quality of Life (MG-QOL-15) score, in neuro-fatigue as measured by Neuro-QOL Fatigue score, or in health status as measured by EQ-5D health status score, after 26 weeks of treatment.

4 . The method of claim 3 , wherein the clinically meaningful improvement the patient experiences is at least a 3 point reduction in the patient's MG-ADL score, at least a 4 point reduction in the patient's QMG score, at least a 6 point reduction in the patient's MGC score, at least a 6 point reduction in the patient's MGC score, at least a 6 point reduction in the patient's MG-QOL-15 score, or at least an 8 point reduction in the patient's Neuro-QOL score, after 26 weeks of treatment.

5 . A method of treating refractory generalized myasthenia gravis in a patient in need thereof comprising administering an eculizumab variant comprising a heavy chain amino acid sequence according to SEQ ID NO: 14 and a light chain amino acid sequence according to SEQ ID NO: 11 to the patient;

wherein the patient is positive for auto-antibodies binding to nicotinic acetylcholine receptor (anti-AChR);

wherein the eculizumab variant is administered at a dose between 600 mg and 6000 mg;

wherein the patient is administered the eculizumab variant for at least 26 weeks;

and

wherein the patient has a clinically meaningful improvement (reduction) in at least two measurements of generalized myasthenia gravis severity selected from the group consisting of MG-ADL, QMG, MGC, MG-QOL, and Neuro-QOL.

6 . The method of claim 1 , wherein the eculizumab variant is administered subcutaneously or by intravenous infusion.

7 . The method of claim 1 , wherein the patient has failed treatment over one year or more with two or more ISTs in sequence or in combination.

8 . The method of claim 1 , wherein the patient has failed at least one IST and requires chronic plasma exchange or IVIg to control symptoms.

9 . The method of claim 1 , wherein the patient experiences a reduction in the administration of one or more IST following at least 26 weeks of treatment.

10 . The method of claim 1 , wherein the patient experiences a reduction in IST dosing following at least 26 weeks of treatment.

11 . The method of claim 1 , wherein the patient experiences a reduction in one or more IST dosing and a discontinuation in one or more IST following at least 26 of treatment.

12 . The method of claim 1 , wherein the patient shows marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving therapy for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability.

13 . The method of claim 5 , wherein the patient shows marked generalized weakness or bulbar signs and symptoms of myasthenia gravis while receiving therapy for myasthenia gravis including anticholinesterase inhibitor therapy and immunosuppressant therapy (IST) and requires chronic plasma exchange or chronic IVIg to maintain clinical stability.

14 . The method of claim 1 , wherein the eculizumab variant is ALXN1210 (BNJ441).

15 . The method of claim 4 , wherein the eculizumab variant is ALXN1210 (BNJ441).

Assignments (1)

Continuity (6)

References Cited (400)